Eloralintide

Eloralintide is described as a selective amylin receptor agonist. In the supplied mechanism text, amylin/IAPP signaling involves receptor complexes formed by the calcitonin receptor with receptor-activity-modifying proteins, with activity in brainstem and hypothalamic regions involved in appetite control. The proposed effect is earlier satiety and reduced food intake. The source also states that lower nausea and vomiting versus injectable GLP-1 drugs was reported in Eloralintide trials, while lean-mass preservation remains unproven.

The supplied research summary reports a Phase 1 proof-of-concept trial published in 2026 by Eli Lilly that randomized 100 adults with obesity across five ascending dose groups. It describes dose-proportional pharmacokinetics and least-squares mean weight reductions from 2.6% to 11.3% at week 12, with nausea at 8% and vomiting at 4%. The source also reports Lilly topline Phase 2 results from November 2025 in 263 adults with obesity or overweight: at 48 weeks, all dose arms exceeded placebo, with mean weight loss ranging from about 9.5% at the lowest dose to 20.1% at 9 mg, compared with 0.4% on placebo. Other reported changes included waist circumference, blood pressure, lipid, and glycemic marker improvements. The source notes mild-to-moderate nausea and fatigue as common adverse events, and it cautions that full peer-reviewed Phase 2 data, head-to-head tirzepatide data, long-term safety, and cardiovascular outcome evidence were not yet available.